The conversation discusses using hair follicle dermal papilla exosomes for hair loss treatment. It inquires about purchasing options for this treatment.
PP405 shows initial promise for treating androgenetic alopecia, with safety confirmed in early trials, but skepticism remains due to limited data. Further trials are needed to determine its true efficacy and potential market impact.
The user is using oral minoxidil, ghk-cu, and HGH for hair regrowth, noticing small vellus hairs on the crown. They avoid traditional DHT blockers like finasteride due to side effects, despite skepticism from others about the effectiveness of ghk-cu.
Exosomes combined with fractional picosecond laser treatment were effective in treating androgenetic alopecia and promoting repigmentation in white hair patches. The role of exosomes in hair repigmentation, particularly in conditions like poliosis, is not well-studied.
Follicum discovered that their drug FOL-005 increased hair count by 12 hairs per cm2 in patients with less than 255 hairs per cm2 and is planning a phase 2b trial. They are currently fundraising for the trial, and the drug may also be effective for women.
Pelage Pharmaceuticals announced positive Phase 2a trial results for PP405 in hair loss therapy. The conversation discusses the delay in publishing full results and the need for further trials and approvals.
IGFBP‐rP1 shows potential for treating androgenic alopecia by influencing hair cycle transitions. Increasing IGF-1 levels may have similar effects to Minoxidil and 5-AR inhibitors in reducing hair loss.
Osteopontin, a protein involved in hair growth on moles, may help with hair loss. However, it is also linked to Alzheimer's, cancer, and bone development, so caution is advised.
The conversation discusses managing seborrheic dermatitis (sebderm) and male pattern baldness (MPB) with treatments like finasteride, coal tar shampoo, Nizoral, and oral minoxidil. Users suggest dietary changes, regular shampooing, and using antifungal products to control sebderm before considering minoxidil.
A user experienced hair thinning and scalp issues after using a sebum-regulating shampoo and perm treatments. They are advised to consider potential allergies, try a simple shampoo, and research treatments like finasteride for possible male pattern baldness.
The post discusses a hair loss treatment regimen using saw palmetto, pumpkin seed oil extract, EGCG (green tea) extract, grape seed oil extract, rosemary oil extract, and Zix. The user plans to use these DHT-blockers and 5AR inhibitors for six months and report the results.
The reduction in scalp oiliness is likely due to finasteride reducing DHT levels and the use of ketoconazole shampoo. The combination of these treatments may have decreased sebum production.
A peptide-based delivery system for finasteride shows promise in reducing systemic side effects while maintaining hair growth effectiveness. Combining this with other treatments like minoxidil and RU58841 could enhance results with lower systemic absorption.
PP405 shows promise in regenerating hair by activating dormant follicles. Other treatments like VDPHL01 and Breezula are also advancing, providing new hope for hair loss solutions.
PP405, developed by Pelage Pharmaceuticals, can reactivate dormant hair follicle stem cells and increase hair growth by 20% in eight weeks, unlike minoxidil or finasteride. However, skepticism remains about its effectiveness and availability, with concerns about funding and the timeline for broader access.
Sulfur soap may help with hair thickening and reducing scalp inflammation, but it can cause dryness. Nizoral, containing ketoconazole, is noted for its potential to reduce seborrheic dermatitis but may also cause scalp dryness and hair loss.
The conversation humorously discusses two resilient hair strands that resist DHT, with mentions of minoxidil and finasteride as ineffective treatments. Users joke about cloning the hairs and the mystery of baldness.
Exploring different treatments for hair loss, such as cosmeRNA and HMI-115 which are small interference messenger RNA that inhibits the DHT receptor and an antibody that binds to the prolactin (PRL) receptor respectively; and researching mechanism and environment of hyperresponders.
The user has been using a combination of finasteride/dutasteride, minoxidil, tretinoin, and hydrocortisone with microneedling and ketoconazole shampoo for hair loss. They are asking if the baby hairs growing will turn into terminal hairs with continued treatment.
SCUBE3, a protein linked to hair growth in moles, was discovered over 25 years ago and is being developed by Amplifica for potential hair loss treatment. Concerns exist about SCUBE3's association with cancer, as it is a protein that promotes cell growth, which could potentially trigger cancer development if used for hair growth therapy.
A user with diffuse hair loss after taking accutane, which might have triggered genetic predisposition to AGA; their experience taking finasteride and experiencing side effects of increased oil production, increased sex drive, worsening hair texture; they are considering zinc supplementation with finasteride or other treatments such as alfatradiol or spironolactone.
Scientists discovered a potential baldness treatment from hairy moles, which can be injected like Botox. Users discussed the treatment's implications, including its safety and effectiveness.
PP405 shows promise in activating dormant hair follicles and increasing hair counts but lacks detailed efficacy data compared to minoxidil and finasteride. Opinions are mixed, with some optimism and skepticism about its effectiveness.
The conversation discusses hair loss treatments, mentioning minoxidil, finasteride, RU58841, VDPHL, GT20029, and follicle cloning as potential solutions. It also reveals that the discussion about PP405 was an April Fool's joke.
New potential hair loss treatment uses molecules from hairy moles to stimulate follicle growth. Topical solution requires less frequent application, like Botox injections a few times per year.
DHT may inhibit hair growth by affecting mitochondrial function, leading to hair follicle miniaturization. Treatments like minoxidil and PP405 may promote hair growth by altering metabolic pathways, potentially counteracting DHT's effects.
Adipose-derived stem cell secretome showed significant improvement in hair density and growth, especially when combined with minoxidil, suggesting a synergistic effect. The study had limitations, including a small sample size and potential bias.
PP405 is anticipated as a future treatment for dormant hair follicles, but its effectiveness and safety are uncertain. Current treatments include oral minoxidil and microneedling, with some avoiding finasteride due to side effects.
Taking CoQ10 and fish oil supplements may lead to increased body hair growth and a crawling sensation on the scalp and skin. The user suspects these supplements could be linked to hair growth, possibly due to their effects on heart health and cholesterol management.
The post discusses the difference in effects of Minoxidil (Min) on scalp and facial hair. The user questions why Min-induced hair growth on the scalp is temporary, while facial hair growth seems permanent, even after stopping Min. They propose theories, including different Min mechanisms on body and facial hair, the role of DHT, and the possibility of not achieving fully terminal hair. The responses include personal experiences and theories about Min's effects on hair growth.